CN102127093B - Refining process for Cefotiam hexetil hydrochloride - Google Patents
Refining process for Cefotiam hexetil hydrochloride Download PDFInfo
- Publication number
- CN102127093B CN102127093B CN 201010600401 CN201010600401A CN102127093B CN 102127093 B CN102127093 B CN 102127093B CN 201010600401 CN201010600401 CN 201010600401 CN 201010600401 A CN201010600401 A CN 201010600401A CN 102127093 B CN102127093 B CN 102127093B
- Authority
- CN
- China
- Prior art keywords
- cefotiam
- add
- salt
- cefotiam hexetil
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229950010227 cefotiam hexetil Drugs 0.000 title claims abstract description 78
- VVFDMWZLBPUKTD-ZKRNHDOASA-N cefotiam hexetil ester Chemical compound O=C([C@@H](NC(=O)CC=1N=C(N)SC=1)[C@H]1SCC=2CSC=3N(N=NN=3)CCN(C)C)N1C=2C(=O)OC(C)OC(=O)OC1CCCCC1 VVFDMWZLBPUKTD-ZKRNHDOASA-N 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000007670 refining Methods 0.000 title abstract description 7
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 claims abstract description 67
- 229960001242 cefotiam Drugs 0.000 claims abstract description 64
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000007789 gas Substances 0.000 claims abstract description 21
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims abstract description 21
- 230000032050 esterification Effects 0.000 claims abstract description 20
- 238000005886 esterification reaction Methods 0.000 claims abstract description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 29
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000000967 suction filtration Methods 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- 238000002425 crystallisation Methods 0.000 claims description 16
- 230000008025 crystallization Effects 0.000 claims description 16
- 235000015320 potassium carbonate Nutrition 0.000 claims description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- 239000001103 potassium chloride Substances 0.000 claims description 14
- 235000011164 potassium chloride Nutrition 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 10
- 239000012065 filter cake Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000010907 mechanical stirring Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 claims description 7
- 238000009423 ventilation Methods 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 235000011181 potassium carbonates Nutrition 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 abstract description 17
- 239000002994 raw material Substances 0.000 abstract description 9
- 238000001953 recrystallisation Methods 0.000 abstract description 9
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 159000000000 sodium salts Chemical class 0.000 abstract 2
- 230000002194 synthesizing effect Effects 0.000 abstract 2
- TYBWWPALTFYPIQ-UHFFFAOYSA-N 1-bromoethyl cyclohexyl carbonate Chemical compound CC(Br)OC(=O)OC1CCCCC1 TYBWWPALTFYPIQ-UHFFFAOYSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- -1 cefotiam compound Chemical class 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229940127249 oral antibiotic Drugs 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000011182 sodium carbonates Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010048946 Anal abscess Diseases 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229960003311 ampicillin trihydrate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000007867 post-reaction treatment Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Landscapes
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a refining process for Cefotiam hexetil hydrochloride prepared by industrial production, which comprises: synthesizing potassium salt or sodium salt of Cefotiam by using Cefotiam hexetil hydrochloride as the raw material; synthesizing Cefotiam hexetil by performing the esterification of the potassium salt or sodium salt of Cefotiam and a brominated material, namely 1-bromo ethyl cyclohexyl carbonate; adding an organic solvent into the Cefotiam hexetil, introducing hydrogen chloride gas to form a salt and precipitating the salt; and finally, obtaining the Cefotiam hexetil hydrochloride by recrystallization. The method is safe, the post treatment is easy, and the product quality is high.
Description
Technical field
The invention belongs to organic synthesis and chemical pharmacy field, the synthesis technique that relates to a kind of compound specifically, is a kind of process for refining of cefotiam hexetil hydrochloride, a kind of by the cefotiam compound, through the method for esterification, salt-forming reaction, synthetic cefotiam hexetil hydrochloride.
Background technology
Cefotiam hexetil can be made into oral antibiotic, this oral antibiotic self there is no anti-microbial effect, to be hydrolyzed to cefotiam rapidly and to be absorbed at intestinal mucosa after oral, cefotiam is identical with in the past oral cynnematin to the anti-microbial activity of gram-positive and negative bacterium, and stable to β-lactamase, the various bacteria such as the streptococcus aureus of clinical separation, coagulase negative staphylococcus, streptococcus pneumoniae, gonococcus, anti-Ampicillin Trihydrate gonococcus all there is stronger anti-microbial activity.The cefotiam hexetil oral antibiotic can be treated the infection such as responsive microbial pharyngolaryngitis, acute bronchitis, tonsillitis, pneumonia, pyelonephritis, urocystitis, pouring mattress urethritis, purulence acne, furuncle, erysipelas, perianal abscess, mazoitis, ocular infection or otitis media.
Therefore the cefotiam hexetil poor stability all is to adopt cefotiam hexetil hydrochloride when preparation and use, and the structural formula of cefotiam hexetil hydrochloride is shown in formula I.
In the existing method for preparing cefotiam hexetil hydrochloride, all use cefotiam (II) to be raw material, through over-churning, the salify two-step reaction makes target compound.But there is following some deficiency in existing technique:
(1) yield is lower.The preparation total recovery of bibliographical information is about 20%, so that the production cost of cefotiam hexetil hydrochloride is difficult to reduce.
(2) byproduct content is relatively high, greater than Japanese Pharmacopoeia specified standards 2%.
(3) the difficult preparation of raw material, on the high side.Document mostly adopts carbonic acid-1-iodo-ethyl ester cyclohexyl and cefotiam to react, and its preparation is difficulty comparatively, and is on the high side.
(4) post-reaction treatment is numerous and diverse.The post-treating method of bibliographical information mainly comes purified product by the multiple extraction of turning one's coat of column chromatography and soda acid, and its production technique is numerous and diverse, is not suitable for the requirement of industrialized production.
Therefore, in the industry in the urgent need to the synthesis technique of the low cefotiam hexetil hydrochloride of a kind of suitable suitability for industrialized production, that reaction and aftertreatment thereof are simple, ripe, yield height and byproduct.
Summary of the invention
For overcoming deficiency of the prior art, the object of the present invention is to provide a kind of simple and safe, cost is lower, aftertreatment is easy, good product quality, the synthesis technique of the preparation cefotiam hexetil hydrochloride that suitability for industrialized is produced namely, is fit to the process for refining of the preparation cefotiam hexetil hydrochloride of suitability for industrialized production.
For solving the problems of the technologies described above, realize expected effect, the following technical scheme that the present invention adopts:
The invention provides a kind of process for refining of cefotiam hexetil hydrochloride, this technique comprises the steps:
(1) adopt cefotiam salt as raw material;
(2) with cefotiam salt and carbonic acid-1-bromine ethyl ester cyclohexyl generation esterification, synthetic cefotiam hexetil;
(3) in cefotiam hexetil, add organic solvent, pass into hydrogen chloride gas, separate out cefotiam hexetil hydrochloride.
Above-mentioned cefotiam salt is cefotiam sylvite or cefotiam sodium salt.
The present invention is take cefotiam salt (cefotiam sylvite or cefotiam sodium salt) as raw material, with more cheap carbonic acid-1-bromine ethyl ester cyclohexyl (III), through the synthetic cefotiam hexetil of esterification, not purifiedly is directly used in that next step is synthetic.It is dissolved in the organic solvent again, passes into dry hydrogen chloride gas, separate out hydrochloride, last recrystallization through the HPLC of " Japanese Pharmacopoeia " regulation check, obtains meeting the product of Japanese Pharmacopoeia definite quality requirement.Described " meeting the Japanese Pharmacopoeia regulation " refers to reference to the correlation detection item (including amount and the cefotiam ester content of related substance) of the cefotiam hexetil hydrochloride quality standard of " Japanese Pharmacopoeia " record and the specified requirement that the resulting detected result of detection method all meets this " Japanese pharmacy ".By dry product, " Japanese Pharmacopoeia " requires every 1mg product to contain cefotiam hexetil hydrochloride with cefotiam (C
18H
23N
9O
4S
3.2HCl; 525.63) meter should be 615 μ g～690 μ g.Cefotiam hexetil assay of the present invention adopts HPLC, and chromatographic column is C18 post 4.0 * 150mm (5 μ m), and moving phase is 0.2mol/L potassium primary phosphate-acetonitrile-Glacial acetic acid (72: 28: 1); The cefotiam hexetil retention time is about 9min; Detect wavelength: 254nm; About 25 ℃ of column temperatures, the result who obtains all meets above-mentioned requirements through replica test.
Raw material cefotiam salt of the present invention is preferably cefotiam sylvite or cefotiam sodium salt, more preferably cefotiam sylvite.It can adopt cefotiam chloride and carbonate (salt of wormwood or yellow soda ash) reaction to obtain.
Above-mentioned cefotiam sylvite or cefotiam sodium salt can synthesize by the following method: in container (for example 500mL three-necked bottle), add methyl alcohol (100mL), under the mechanical stirring, cool to 0 ℃ and add cefotiam chloride (20g (about 0.035mol)); Dissolving obtains the cefotiam chloride methanol solution, adds salt of wormwood (or yellow soda ash) 9.6g (0.07mol) at 0 ℃ more in batches, stirs (approximately 2h); Suction filtration adds acetone (100ml) and places-5 ℃ of lower continuation to stir (approximately 2h) in the filtrate, crystallization, and suction filtration, 40 ℃ of drying under reduced pressure obtain cefotiam sylvite or cefotiam sodium salt.
In the above-mentioned synthesis technique of the present invention, the described cefotiam salt of step (2) is under salt of wormwood and/or sodium carbonates' presence, and carbonic acid-1-bromine ethyl ester cyclohexyl generation esterification, synthetic cefotiam hexetil; The described organic solvent that in cefotiam hexetil, adds of step (3), this organic solvent is selected from arbitrary or its arbitrary combination among methylene dichloride, acetone, ether, ethyl acetate, acetonitrile, the THF; Preferred methylene dichloride or ethyl acetate; More preferably ethyl acetate.
In sum, the invention provides a kind of synthesis technique of cefotiam hexetil hydrochloride, this synthesis technique is in fact a kind of process for refining, and wherein, this technique comprises the steps:
(1) cefotiam chloride and carbonate reaction prepare cefotiam salt;
(2) above-mentioned preparation gained cefotiam salt is under salt of wormwood or sodium carbonates' presence, and carbonic acid-1-bromine ethyl ester cyclohexyl generation esterification; Esterification is spin-dried for solvent after finishing, and judges that the method that esterification finishes is to get final product fully through HPLC monitoring raw material reaction;
(3) the reactant adding that step (2) is obtained is selected from the organic solvent of arbitrary or its combination among methylene dichloride, acetone, ether, ethyl acetate, acetonitrile, the THF; Pass into hydrogen chloride gas, separate out cefotiam hexetil hydrochloride;
(4) cefotiam hexetil hydrochloride that step (3) is obtained is preferably used 10 times methyl alcohol: after the solution heating for dissolving of sherwood oil=1: 5, the cooling crystallization filters and obtains cefotiam hexetil hydrochloride.
Methyl alcohol in the above-mentioned steps (4) and the solution of sherwood oil are about methyl alcohol: sherwood oil=1: 2～methyl alcohol of 1: 10 and the solution of sherwood oil, consumption is approximately 5 times～50 times of hydrochloride that step (3) obtains, in a preferred embodiment, preferably use about 10 times methyl alcohol: the solution heating for dissolving of sherwood oil=1: 5.
In the above-mentioned synthesis technique, described cefotiam sylvite, the cefotiam sodium salt can synthesize by the following method: be selected from methyl alcohol in adding, ethanol, reaction solvent (the particular methanol of arbitrary or its combination in the acetonitrile, methyl alcohol 100mL for example) in the container (generic container is selected the 500mL three-necked bottle), arrive-10～10 ℃ (preferred 0 ℃) at the mechanical stirring borehole cooling, add cefotiam chloride, the quality of this cefotiam chloride is 1: 3～1: 10 (for example, adding cefotiam chloride 20g (about 0.035mol)) with the ratio of the volume of this reaction solvent; Dissolving obtains the cefotiam chloride methanol solution, add carbonate at-10～10 ℃ (preferred 0 ℃) more in batches, the reaction mol ratio of cefotiam chloride and carbonate is 1: 1～1: 3, this carbonate is salt of wormwood or yellow soda ash (amount of carbonate is 9.6g (0.07mol) for example), stirring reaction 1.5～3h (about 2h); Suction filtration adds acetone (for example 100ml) and places-10～10 ℃ (preferred 0 ℃～-5 ℃) lower continuation to stir (approximately 2h) in the filtrate, crystallization, and suction filtration, 40 ℃ of lower drying under reduced pressure obtain cefotiam sylvite or cefotiam sodium salt.
In the above-mentioned synthesis technique, described cefotiam hexetil is the ethyl acetate solution of cefotiam hexetil, it can synthesize by the following method: add THF (200ml) in the 500ml reaction flask, be cooled to 3 ℃, add cefotiam potassium or cefotiam sodium salt 10g (about 0.018mol), be stirred to dissolve complete, add Anhydrous potassium carbonate or anhydrous sodium carbonate, the mol ratio of this cefotiam salt and salt of wormwood or yellow soda ash is 1: 0.5～1: 2, (for example add salt of wormwood 2.42g, about 0.018mol), add carbonic acid-1-bromine ethyl ester cyclohexyl 8.75g (0.035mol), the reaction mol ratio of described cefotiam salt and carbonic acid-1-bromine ethyl ester cyclohexyl is 1: 1～1: 3; Stir, carry out esterification; After reacting completely, the lower evaporate to dryness THF of room temperature decompression adds organic solvent (for example methylene dichloride or ethyl acetate 100ml) dissolving again, filters, and gets the organic solvent solution of cefotiam hexetil, namely the ethyl acetate solution of cefotiam hexetil.
In synthesis technique of the present invention, also comprise: the ethyl acetate solution of described cefotiam hexetil is cooled to sub-zero zero, slowly pass into dry hydrogen chloride gas, until stop ventilation when separating out without solid again, separate out white solid and be cefotiam hexetil hydrochloride.
White solid obtained above is the cefotiam hexetil hydrochloride crude product, in order to obtain better the higher cefotiam hexetil hydrochloride of purity, preferred following purification step: with the crude product suction filtration, filter cake methyl alcohol: sherwood oil 1: 2～10 solution weight crystallizations get cefotiam hexetil hydrochloride.
The above-mentioned process that obtains the cefotiam hexetil hydrochloride highly finished product can be summarized as: the ethyl acetate solution of cefotiam hexetil obtained above (the ethyl acetate solution solution 100ml that for example adds prepared cefotiam hexetil in the 500mL reaction flask) (for example-10～0 ℃ is cooled to sub-zero zero, preferably approximately-5 ℃), slowly pass into dry hydrogen chloride gas, the adularescent solid is separated out; Until stop ventilation when separating out without solid again.Suction filtration, filter cake methyl alcohol: the petroleum ether solution recrystallization gets cefotiam hexetil hydrochloride.
In the above-mentioned involved re-crystallization step, the recrystallization solvent of employing is methyl alcohol: sherwood oil 1: 2～1: 10, this is volume ratio, particular methanol: sherwood oil 1: 5.
In the above-mentioned synthesis technique, (3) step wherein is specially and is spin-dried for solvent after esterification finishes, and adds organic solvent, then passes into hydrogen chloride gas, separates out hydrochloride; It is the committed step of purge process of the present invention, determined and product can have been separated out the hydrochloride solid to greatest extent, thereby crystallization obtains the cefotiam hexetil hydrochloride of high purity, high yield, so the organic solvent that the present invention uses this step is optimized:
Select methylene dichloride, ethyl acetate, acetone, acetonitrile, THF and these several those skilled in the art of ether used organic solvent when testing, they are compared test.
1) reactants dissolved that step (2) is obtained cools to-5 ℃ in the 100ml ethyl acetate, slowly passes into dry hydrogen chloride gas, and the adularescent solid is separated out; Until stop ventilation when separating out without solid again.Suction filtration is weighed behind the filter cake drying under reduced pressure, crude product yield 72.5%.
2) reactants dissolved that step (2) is obtained cools to-5 ℃ in the 100ml methylene dichloride, slowly passes into dry hydrogen chloride gas, and the adularescent solid is separated out; Until stop ventilation when separating out without solid again.Suction filtration is weighed behind the filter cake drying under reduced pressure, crude product yield 60.7%.
3) reactants dissolved that step (2) is obtained cools to-5 ℃ in 100ml acetone, slowly passes into dry hydrogen chloride gas, has a small amount of white solid to separate out.
4) reactants dissolved that step (2) is obtained cools to-5 ℃ in the 100ml acetonitrile, slowly passes into dry hydrogen chloride gas, and liquid is muddy, does not obtain the solid precipitate.
5) reactants dissolved that step (2) is obtained cools to-5 ℃ in 100ml THF, slowly passes into dry hydrogen chloride gas, and liquid is muddy, does not obtain the solid precipitate.
6) reactants dissolved that step (2) is obtained cools to-5 ℃ in the 100ml ether, slowly passes into dry hydrogen chloride gas, only has a small amount of white solid to separate out.
More experimental data since length limit and owe temporarily to give.
Can be found out that by above-mentioned data acetonitrile, THF can not produce crystallization during as solvent; The organic solvents such as methylene dichloride, acetone, ether, ethyl acetate have crystallization during as solvent; When wherein methylene dichloride, ethyl acetate were as solvent, crystallization output was the highest.
Therefore, the present invention through repetition test, has finally obtained to be fit to preferred organic solvent dichloromethane of the present invention or ethyl acetate by the conventional organic solvent that adopts in this area has been carried out a large amount of screenings; For particular case of the present invention, in a preferred embodiment, the most preferred organic solvent of the present invention is ethyl acetate.
The step of building-up reactions of the present invention (2) be cefotiam salt in the presence of carbonate, and carbonic acid-1-bromine ethyl ester cyclohexyl generation esterification.The temperature of esterification is-5～10 ℃, and the reaction times is 15～30min, and the product of esterification is cefotiam hexetil.Wherein, described carbonate is salt of wormwood or yellow soda ash, and this carbonate mainly plays catalyzer, and take salt of wormwood as example, its consumption is cefotiam salt: salt of wormwood=1: (0.5～2), this is mol ratio.Carbonic acid-1-bromine ethyl ester cyclohexyl is reactant, and the reaction mol ratio of cefotiam salt and carbonic acid-1-bromine ethyl ester cyclohexyl is 1: (1～3).Solvent for use is THF, because its boiling point is low, is easy to remove at low temperatures.The ratio of cefotiam salt and THF is 1: 15～1: 30 (weight: volume).
In the above-mentioned steps (2), the optional ethyl acetate of organic solvent, methylene dichloride, acetone and the ether of last solubilizing reaction thing, ethyl acetate or methylene dichloride; More preferably ethyl acetate.
In another preferred embodiment, raw material cefotiam salt of the present invention is preferably cefotiam sylvite, it can synthesize by the following method: in container (for example 500mL three-necked bottle), add methyl alcohol (100mL), under the mechanical stirring, cool to 0 ℃ and add cefotiam chloride (20g, about 0.035mol); Dissolving obtains the cefotiam chloride methanol solution, adds salt of wormwood (9.6g, 0.07mol) at 0 ℃ more in batches, stirs about 2h; Suction filtration adds acetone (100ml) and places-5 ℃ of lower about 2h of stirring that continue in the filtrate, crystallization, and suction filtration, 40 ℃ of drying under reduced pressure obtain cefotiam sylvite.
The present invention is take cefotiam as raw material, with carbonic acid-1-bromine ethyl ester cyclohexyl (III), through the synthetic cefotiam hexetil of esterification, again it is dissolved in the organic solvent, passes into dry hydrogen chloride gas, separate out hydrochloride, last recrystallization obtains satisfactory final product.
Final product obtained above is analyzed through HPLC according to the correlation detection condition of Japanese Pharmacopoeia record, the checks such as titration, and the result meets the requirement of Japanese Pharmacopoeia definite quality.
THF described in the present invention is the abbreviation of tetrahydrofuran (THF).
One of compared with prior art, the present invention has following advantage:, be in esterification, change habitual carbonic acid-1-iodo-ethyl ester cyclohexyl into more with low cost, the carbonic acid that conveniently is easy to get-1-bromine ethyl ester cyclohexyl; Two, the cefotiam hexetil that obtains of reaction is not purified to be directly used in next step reaction, has simplified production process, reduces the loss, and has improved yield; Three in salt-forming reaction, change into and directly pass into hydrogen chloride gas, separate out hydrochloride, simplified post-treating method, the requirement of more suitable industrialized production.
Embodiment
For more clear explanation goal of the invention and technical scheme, be described in further detail by following embodiment.
The preparation method of embodiment 1 cefotiam hexetil hydrochloride
1) cefotiam salt is synthetic
In the 500ml three-necked bottle, add 100ml methyl alcohol, mechanical stirring borehole cooling to 0 ℃ adding cefotiam chloride 20.00g (0.035mol); Dissolving obtains the cefotiam chloride methanol solution, adds salt of wormwood 9.66g (0.07mol) at 0 ℃ more in batches, stirs 2h.Suction filtration adds acetone 100ml and places-5 ℃ of lower stirring 2h that continue in the filtrate, crystallization, and suction filtration, 40 ℃ of drying under reduced pressure obtain cefotiam sylvite 27.07g.
2) cefotiam ester synthesis
In the 500ml reaction flask, add THF200ml, be cooled to 3 ℃, add cefotiam potassium 13.50g (0.018mol), be stirred to dissolve complete, add Anhydrous potassium carbonate 2.42g (0.018mol), add carbonic acid-1-bromine ethyl ester cyclohexyl 8.80g (0.035mol), stir, carry out esterification; After reacting completely, the lower evaporate to dryness THF of room temperature decompression adds ethyl acetate 100ml again, filters, and gets the ethyl acetate solution of cefotiam hexetil.
3) cefotiam hexetil hydrochloride is synthetic
Add the ethyl acetate solution of prepared cefotiam hexetil of step in the 500ml reaction flask, cool to-5 ℃, slowly pass into dry hydrogen chloride gas, the adularescent solid is separated out, until stop ventilation when separating out without solid again.Suction filtration, filter cake methyl alcohol: the solution 100ml of sherwood oil=1: 5 is heated to 50 ℃ of dissolvings, is cooled to 0 ℃ of crystallization, gets cefotiam hexetil hydrochloride 8.58g.
In the present embodiment, the yield of white cefotiam hexetil hydrochloride is 62.0%, detects through HPLC, and its isomery ratio is A
a/ (A
a+ A
b)=0.49, purity are 98.5%.
The preparation method of embodiment 2 cefotiam hexetil hydrochlorides
1) cefotiam salt is synthetic
In the 500ml three-necked bottle, add 100ml methyl alcohol, mechanical stirring borehole cooling to 0 ℃ adding cefotiam chloride 20.00g (0.035mol); Dissolving obtains the cefotiam chloride methanol solution, adds salt of wormwood 9.66g (0.07mol) at 0 ℃ more in batches, stirs 2h.Suction filtration adds acetone 100ml and places-5 ℃ of lower stirring 2h that continue in the filtrate, crystallization, and suction filtration, 40 ℃ of drying under reduced pressure obtain cefotiam sylvite 27.07g.
2) cefotiam ester synthesis
In the 500ml reaction flask, add THF200ml, be cooled to 3 ℃, add cefotiam potassium 13.50g (0.018mol), be stirred to dissolve complete, add Anhydrous potassium carbonate 2.42g (0.018mol), add carbonic acid-1-bromine ethyl ester cyclohexyl 8.80g (0.035mol), stir, carry out esterification; After reacting completely, the lower evaporate to dryness THF of room temperature decompression adds methylene dichloride 100ml again, filters, and gets the dichloromethane solution of cefotiam hexetil.
3) cefotiam hexetil hydrochloride is synthetic
Spore is cooled to-5 ℃ for the dichloromethane solution of peace ester, slowly pass into dry hydrogen chloride gas and pass into dry hydrogen chloride gas, separate out the white hydrochloride salt solid, filter, filter cake methyl alcohol: the solution 100ml recrystallization of sherwood oil=1: 5 gets cefotiam hexetil hydrochloride 7.81g.
In the present embodiment, the yield of white cefotiam hexetil hydrochloride is 56.4%, detects through HPLC, and its isomery ratio is A
a/ (A
a+ A
b)=0.49, purity are 98.6%.
The preparation method of embodiment 3 cefotiam hexetil hydrochlorides
1) cefotiam salt is synthetic
In the 500ml three-necked bottle, add 100ml ethanol, mechanical stirring borehole cooling to 0 ℃ adding cefotiam chloride 20.00g (0.035mol); Dissolving obtains the cefotiam chloride ethanolic soln, adds salt of wormwood 9.66g (0.07mol) at 0 ℃ more in batches, stirs 2h.Suction filtration adds acetone 100ml and places-5 ℃ of lower stirring 2h that continue in the filtrate, crystallization, and suction filtration, 40 ℃ of drying under reduced pressure obtain cefotiam sylvite 26.63g.
2) cefotiam ester synthesis
In the 500ml reaction flask, add THF200ml, be cooled to 3 ℃, add cefotiam potassium 13.50g (0.018mol), be stirred to dissolve complete, add Anhydrous potassium carbonate 2.42g (0.018mol), add carbonic acid-1-bromine ethyl ester cyclohexyl 8.75g (0.035mol), stir, carry out esterification; After reacting completely, the lower evaporate to dryness THF of room temperature decompression adds ethyl acetate 100ml again, filters, and gets the ethyl acetate solution of cefotiam hexetil.
3) cefotiam hexetil hydrochloride is synthetic
Add the ethyl acetate solution of prepared cefotiam hexetil of step in the 500ml reaction flask, cool to-5 ℃, slowly pass into dry hydrogen chloride gas, the adularescent solid is separated out, until stop ventilation when separating out without solid again.Suction filtration, filter cake methyl alcohol: the solution 100ml recrystallization of sherwood oil=1: 5 gets cefotiam hexetil hydrochloride 7.50g.
In the present embodiment, the yield of white cefotiam hexetil hydrochloride is 54.2%, detects through HPLC, and its isomery ratio is A
a/ (A
a+ A
b)=0.48, purity are 98.3%.
The preparation method of embodiment 4 cefotiam hexetil hydrochlorides
1) cefotiam salt is synthetic
In the 500ml three-necked bottle, add 100ml methyl alcohol, mechanical stirring borehole cooling to 0 ℃ adding cefotiam chloride 20.00g (0.035mol); Dissolving obtains the cefotiam chloride methanol solution, adds yellow soda ash 7.42g (0.07mol) at 0 ℃ more in batches, stirs 2h.Suction filtration adds acetone 100ml and places-5 ℃ of lower stirring 2h that continue in the filtrate, crystallization, and suction filtration, 40 ℃ of drying under reduced pressure obtain cefotiam sodium salt 24.73g.
2) cefotiam ester synthesis
In the 500ml reaction flask, add THF200ml, be cooled to 3 ℃, add cefotiam sodium 12.83g (0.018mol), be stirred to dissolve complete, add anhydrous sodium carbonate 1.91g (0.018mol), add carbonic acid-1-bromine ethyl ester cyclohexyl 8.75g (0.035mol), stir, carry out esterification; After reacting completely, the lower evaporate to dryness THF of room temperature decompression adds ethyl acetate 100ml again, filters, and gets the ethyl acetate solution of cefotiam hexetil.
3) cefotiam hexetil hydrochloride is synthetic
Spore passes into dry hydrogen chloride gas for the ethyl acetate solution of peace ester, separates out the white hydrochloride salt solid, filters filter cake methyl alcohol: the solution 100ml recrystallization of sherwood oil=1: 5 gets cefotiam hexetil hydrochloride 8.06g.
In the present embodiment, the yield of white cefotiam hexetil hydrochloride is 58.3%, detects through HPLC, and its isomery ratio is A
a/ (A
a+ A
b)=0.49, purity are 98.1%.
A in above-described embodiment
a, A
bTwo isomery composition peak areas for cefotiam hexetil hydrochloride.
More than described the preferred embodiment for the present invention, so it is not to limit the present invention.Those skilled in the art are not to can departing from improvement and the variation of category of the present invention and spirit in a little disclosed embodiments.
Claims (1)
1. the exquisite technique of a cefotiam hexetil hydrochloride, the method comprises the steps:
1) in the 500ml three-necked bottle, adds 100ml methyl alcohol, mechanical stirring borehole cooling to 0 ℃ adding cefotiam chloride 20.00g; Dissolving obtains the cefotiam chloride methanol solution, adds salt of wormwood 9.66g at 0 ℃ more in batches, stirs 2h; Suction filtration adds acetone 100ml and places-5 ℃ of lower stirring 2h that continue in the filtrate, crystallization, suction filtration, 40 ℃ of drying under reduced pressure obtain cefotiam sylvite 27.07g;
2) in the 500ml reaction flask, add THF200ml, be cooled to 3 ℃, add cefotiam potassium 13.50g, be stirred to dissolve complete, add Anhydrous potassium carbonate 2.42g, add carbonic acid-1-bromine ethyl ester cyclohexyl 8.80g, stir, carry out esterification; After reacting completely, the lower evaporate to dryness THF of room temperature decompression adds ethyl acetate 100ml again, filters, and gets the ethyl acetate solution of cefotiam hexetil;
3) add the ethyl acetate solution of prepared cefotiam hexetil of step in the 500ml reaction flask, cool to-5 ℃, slowly pass into dry hydrogen chloride gas, the adularescent solid is separated out, until stop ventilation when separating out without solid again; Suction filtration, filter cake methyl alcohol: the solution 100ml of sherwood oil=1: 5 is heated to 50 ℃ of dissolvings, is cooled to 0 ℃ of crystallization, gets cefotiam hexetil hydrochloride 8.58g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010600401 CN102127093B (en) | 2010-12-22 | 2010-12-22 | Refining process for Cefotiam hexetil hydrochloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010600401 CN102127093B (en) | 2010-12-22 | 2010-12-22 | Refining process for Cefotiam hexetil hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102127093A CN102127093A (en) | 2011-07-20 |
| CN102127093B true CN102127093B (en) | 2013-03-20 |
Family
ID=44265394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010600401 Expired - Fee Related CN102127093B (en) | 2010-12-22 | 2010-12-22 | Refining process for Cefotiam hexetil hydrochloride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102127093B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104031068A (en) * | 2014-06-11 | 2014-09-10 | 济南诚汇双达化工有限公司 | Method of preparing cefotiam hexetil hydrochloride by one-pot method |
| CN106749334A (en) * | 2016-11-23 | 2017-05-31 | 扬子江药业集团北京海燕药业有限公司 | A kind of preparation method of high-purity cefotiam hexetil dihydrochloride |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101619069A (en) * | 2009-07-28 | 2010-01-06 | 余小强 | Preparation method of cefotiam hexetil hydrochloride |
-
2010
- 2010-12-22 CN CN 201010600401 patent/CN102127093B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102127093A (en) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106810426B (en) | Method for synthesizing cannabidiol | |
| CN101619069A (en) | Preparation method of cefotiam hexetil hydrochloride | |
| CN107778223B (en) | Preparation method of betrixaban maleate | |
| CN103554201B (en) | Gamithromycin preparation method | |
| CN106279104B (en) | A kind of process modification method preparing amber love song Ge Lieting | |
| CN110183367A (en) | A kind of synthetic method of (3R, 4S) -1- benzyloxycarbonyl group -4- N-ethyl pyrrole N -3- carboxylic acid suitable for industrialization | |
| CN102395591B (en) | Method for preparing prasugrel | |
| CN107033212A (en) | A kind of ursolic acid derivative with anti-inflammatory activity and its production and use | |
| CN112679420A (en) | Preparation method of 2,5-dibromopyridine | |
| CN112592356A (en) | Method for synthesizing lornoxicam | |
| CN102127093B (en) | Refining process for Cefotiam hexetil hydrochloride | |
| CN101475539B (en) | Refining method for preparing high-purity oteracil potassium | |
| CN106977512A (en) | The method for preparing the smooth free alkali of horse sieve | |
| CN109694359B (en) | Synthetic method of nitrofuran metabolite-furazolidone AOZ-D4 | |
| CN101990528B (en) | Catechol manufacturing method | |
| CN111100042B (en) | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | |
| CN103254156A (en) | Preparation method of afatinib intermediate | |
| CN106674205A (en) | Sartan compound discoloration method | |
| CN101492388A (en) | Method for synthesis of Miqujing medicament material | |
| CN113248465B (en) | Synthetic method of biochanin A | |
| CN115850244B (en) | Preparation method of topiroxostat | |
| CN109651234A (en) | A kind of synthetic method of Doneppezil Hydrochloride | |
| CN114213343B (en) | Preparation and purification methods of celecoxib intermediate | |
| CN115677456B (en) | Preparation method of cannabidiol | |
| CN113943281B (en) | Synthetic method and application of isoxazole pyrimidine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU HANSES PHARMACEUTICAL RESEARCH + DEVELOP Free format text: FORMER OWNER: XU JIAXIANG Effective date: 20130122 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 150001 HARBIN, HEILONGJIANG PROVINCE TO: 510330 GUANGZHOU, GUANGDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130122 Address after: 205, room 510330, Haizhu science and technology building, 2429 East Xingang Road, Guangzhou, Guangdong Applicant after: Guangzhou Hanses Pharmaceutical Research & Development Co., Ltd. Address before: 150001, Ma 302 street, Nangang District, Heilongjiang, Harbin Applicant before: Xu Jiaxiang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XIZANG HANSES PHARMACEUTICAL DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: GUANGZHOU HANSES PHARMACEUTICAL RESEARCH + DEVELOPMENT CO., LTD. Effective date: 20140722 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510330 GUANGZHOU, GUANGDONG PROVINCE TO: NYINGCHI PREFECTURE, TIBET AUTONOMOUS REGION |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140722 Address after: No. 31 east section of Fuzhou Road, Linzhi District, Tibet Tibetan Autonomous Region Patentee after: Tibet and rattan pharmaceutical development Limited by Share Ltd Address before: 205, room 510330, Haizhu science and technology building, 2429 East Xingang Road, Guangzhou, Guangdong Patentee before: Guangzhou Hanses Pharmaceutical Research & Development Co., Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Tibet and rattan pharmaceutical development Limited by Share Ltd Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Tibet and rattan pharmaceutical development Limited by Share Ltd Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130320 Termination date: 20181222 |